A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.

Abstract : Glioblastoma is the most frequent and malignant brain tumour. For many years, the conventional treatment has been maximal surgical resection followed by radiotherapy (RT), with a median survival time of less than 10 months. Previously, the use of adjuvant chemotherapy (given after RT) has failed to demonstrate a statistically significant survival advantage. Recently, a randomized phase III trial has confirmed the benefit of temozolomide (TMZ) and has defined a new standard of care for the treatment of patients with high-grade brain tumours. The results showed an increase of 2.5 months in median survival, and 16.1 % in 2 year survival, for patients receiving RT with TMZ compared with RT alone. It is not clear whether the major benefit of TMZ comes from either concomitant administration of TMZ with RT, or from six cycles of adjuvant TMZ, or both.
Document type :
Journal articles
Complete list of metadatas

Cited literature [50 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-00554654
Contributor : Hal Peer <>
Submitted on : Tuesday, January 11, 2011 - 3:25:56 AM
Last modification on : Tuesday, February 12, 2019 - 9:26:01 AM

File

PEER_stage2_10.1016%2Fj.jtbi.2...
Files produced by the author(s)

Identifiers

Collections

Citation

Lara Barazzuol, Neil G. Burnet, Raj Jena, Bleddyn Jones, Sarah J. Jefferies, et al.. A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.. Journal of Theoretical Biology, Elsevier, 2009, 262 (3), pp.553. ⟨10.1016/j.jtbi.2009.10.021⟩. ⟨hal-00554654⟩

Share

Metrics

Record views

102

Files downloads

609